| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA820: Brolucizumab for treating diabetic macular oedema |
|
Medicine details |
|
| Medicine name | brolucizumab (Beovu®) |
| Formulation | 120 mg/ml solution for intravitreal injection |
| Reference number | 4467 |
| Indication | Treatment of visual impairment due to diabetic macular oedema (DME) in adults |
| Company | Novartis Pharmaceuticals UK Ltd |
| BNF chapter | Eye |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 09/12/2021 |
| NICE guidance | |
| Commercial arrangement | TBC |